Rik Deitsch, President, CEO and Director of Nutra Pharma (NPHC) talked to The Wall Street Transcript about his company Nutra Pharma.  Click here to read the complete interview.

TWST: Would you please tell us about Nutra Pharma?

Mr. Deitsch: Nutra Pharma (NPHC.OB), for want of a better term, is a biotechnology holding company. We seek out interesting concepts, drugs and devices in the biotechnology field, and we bring it into the Nutra Pharma family. We are especially good at finding diamonds in the rough – companies that are poorly managed and/or undercapitalized, and bring them competent management, qualified business plans and then necessary funding. Utilizing this strategy, we now have two divisions: ReceptoPharm is our drug discovery division and Designer Diagnostics is our medical device division. In ReceptoPharm we have drugs for the treatment of HIV, multiple sclerosis (MS), rheumatoid arthritis, adrenomyeloneuropathy (AMN) and pain. In Designer Diagnostics we have medical devices for the rapid isolation and detection of mycobacteria, which are bacteria that are very hard to culture and grow.

This entry was posted on Monday, November 2nd, 2009 at 2:30 pm and is filed under Healthcare Stocks. You can follow any responses to this entry through the RSS 2.0 feed.